Table 3 Efficacy, coverage and adherence values used in base-case analysis
From: Cost-effectiveness analysis of interventions for migraine in four low- and middle-income countries
Intervention | Efficacy | Coverage | Provider adherence | Patient adherence | |||
|---|---|---|---|---|---|---|---|
| Â | Â | Current | Target | Current | Target | Current | Target |
Drugs providing sustained headache relief | Â | Â | Â | Â | Â | Â | |
ASA 1,000 mg | 39% [21] | 80% | 90% | 100% | 100% | 80% | 90% |
(Zambia 50%) | |||||||
Sumatriptan 50 mg | 35% [19] | 2% | (Zambia 80%) | 75% | 88% | 56% | 78% |
(Zambia 1%) | |||||||
Almotriptan 12.5 mg | 45% [20] | 0% | 75% | 88% | 56% | 78% | |
Drugs averting migraine attacks | Â | Â | Â | Â | Â | Â | |
Propranolol 160 mg | 28% [22] | 3% | 30% | 75% | 88% | 71% | 86% |
Topiramate 100 mg | 40% [23] | 1% | 75% | 88% | 60% | 80% | |
Amitriptyline 100 mg | 44% [24] | 3% | 75% | 88% | 42% | 71% | |